137862-87-4,
(R)-2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid,
D-Valsartan,
UNII-IDC67444MI,
CGP-49309,
CHEMBL115622,
IDC67444MI,
(2R)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid,
Valsartan, D-,
D-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,
(2R)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid,
Valsartan related compound A,
ent-Valsartan,
D-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-,
NCGC00095139-01,
Valsartan related compound A [USP],
Valsartan specified impurity A [EP],
Valsartan related compound A RS [USP],
AC1NR4SZ,
DSSTox_CID_3735,
SCHEMBL2328,
DSSTox_RID_77173,
DSSTox_GSID_23735,
DTXSID6023735,
CTK8B5685,
ZINC3831602,
Tox21_111447,
ANW-49605,
BDBM50282371,
MFCD18252868,
AKOS015854410,
AKOS026751459,
API0012846,
(2R)-3-Methyl-2-(pentanoyl((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)amino)butanoic acid,
AK-39369,
BR-39369,
AB0068858,
AX8164352,
TR-005022,
CAS-137862-53-4,
FT-0675772,
ST24026402,
S-7514,
A807313,
J-007070,
(R)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-Methyl)-valine,
[(R-N-valeryl-N-([2'-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine),
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-D-valine,
(2R)-3-Methyl-2-[pentanoyl[[2'(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoic Acid,
N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-D-valine,
Valsartan Related Compound A, United States Pharmacopeia (USP) Reference Standard,
(2R)-3-methyl-2-[1-oxopentyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid,
(2R)-3-methyl-2-[pentanoyl-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid,
(2R)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid,
(2R)-3-Methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoic Acid (Valsartan (R)-Enantiomer),
(r)-2-(n-((2-(1h-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid,
(R)-2-(N-((2;-(1H-Tetrazol-5-yl)-[1,1;-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid,
(R)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid,
N-VALERYL-N-{[2'-(1HTETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-D-VALINE(ent-Valsartan)(Valsartan Related Compound A), Pharmaceutical Secondary Standard; Certified Reference Material,
valsartan,
(R)-Valsartan,
Valsartan EP impurity A,
ACN-026591,
CB11820,
CID5284633,
CS-O-08393,
137862-53-4,
((R)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine),
(R)-[N-VALERYL-N-([2'-(1H-TETRAZOLE-5-YL)BIPHEN-4-YL]METHYL)VALINE),